Randomized phase III trial of chemoimmunotherapy in patients with previously untreated stage III, optimal disease ovarian cancer: A Southwest Oncology Group study
- 1 January 1989
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 32 (1) , 16-21
- https://doi.org/10.1016/0090-8258(89)90842-1
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Randomized phase III trial of chemoimmunotherapy in patients with previously untreated stages III and IV suboptimal disease ovarian cancer: A Southwest Oncology Group studyGynecologic Oncology, 1989
- Cancer Statistics, 1987CA: A Cancer Journal for Clinicians, 1987
- Therapy of stage III (optimal) epithelial carcinoma of the ovary with melphalan or melphalan plus corynebacterium parvum (a gynecologic oncology group study)Gynecologic Oncology, 1986
- The potential for optimal (⩽ 2 cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center: A prospective studyGynecologic Oncology, 1986
- A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group studyCancer, 1986
- Cancer Statistics, 1986CA: A Cancer Journal for Clinicians, 1986
- Long-term survival after chemotherapy for advanced epithelial ovarian carcinomaAmerican Journal of Obstetrics and Gynecology, 1984
- Combination chemotherapy with adriamycin-cyclophosphamide for advanced ovarian carcinomaCancer, 1980
- Advanced Ovarian Adenocarcinoma A Prospective Clinical Trial of Melphalan (L-PAM) Versus Combination ChemotherapyObstetrical & Gynecological Survey, 1979
- Advanced Ovarian AdenocarcinomaNew England Journal of Medicine, 1978